FIBREX Medical Inc.: News - Press Releases

Ikaria Holdings, Inc. and Fibrex Medical, Inc. today announced that Ikaria has entered into an agreement under which Ikaria has acquired the exclusive worldwide license to Fibrex Medical's portfolio of investigational compounds for a range of critical care conditions.

The investigational compounds, which are known as FX06, FX201, and FX107, are fibrin-derived peptides that bind to vascular endothelial cells, preserving endothelial barrier function and preventing tissue injury. These novel peptides, which are modified fragments of naturally occurring proteins, are being developed to augment the body's natural protective mechanisms by preventing vascular leakage, leukocyte transmigration, and capillary vasoconstriction. The compelling mechanisms of action of these compounds, which have demonstrated biological activity in a multitude of animal disease models, hold great promise for exploration in a multitude of critical care conditions in which they play important pathogenic roles.

Through Phase I and II human trials, as well as through animal disease models, FX06 has shown evidence of a well characterized safety profile and mechanism of action, offering significant promise for many critical care conditions which Ikaria is targeting in its research & development efforts. FX107 and FX201 provide the same clinical promise, although with modified pharmacokinetic profiles.

"Acquiring the global license to the Fibrex portfolio is consistent with our mission to deliver therapies which address the significant unmet needs of the millions of patients who are hospitalized with serious conditions caused or complicated by vascular leakage and resulting extravasion and tissue injury," commented Daniel Tassé, President and CEO of Ikaria. "Great products are born from superb clinical insight that is married with a deep understanding of the biology of the conditions affecting critically ill patients. That is why we are enthusiastic about this portfolio."

"We are proud of the pipeline we have built around our completely novel mechanism of action and very excited to enter into this agreement with Ikaria to complete development and commercialization," stated Dr. Rainer Henning, President and CEO of Fibrex Medical. "We are delighted to partner with Ikaria with its unwavering commitment to delivering novel therapies to critically ill patients around the world."

Fibrex Medical will receive upfront and milestone payments, as well as royalties on net sales. Ikaria will be responsible for pre-clinical and clinical development activities, as well as for commercialization.

About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOMAX^® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOMAX is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOMAX, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

About Fibrex Medical, Inc.
Fibrex Medical Inc. is a privately held company headquartered in Cambridge, MA, USA with operations in Vienna, Austria. The Company is developing innovative therapeutics for acute and intensive care in cardiovascular and inflammatory conditions based on novel mechanisms of action. Fibrex Medical started operations in 2001, and has raised Euro 14 M in investments from top tier venture capital investors including Atlas Venture, Global Life Science Ventures, EMBL Ventures and Mulligan Biocapital. For more information, please visit www.fibrexmedical.com.


CONTACT:
Samina Bari Ikaria 908.238.6372 Samina.bari@ikaria.com		Rainer Henning, PhD Fibrex Medical, Inc. +43-(0)1-890 0617 rainer.henning@fibrexmedical.com

[ Download this press release as pdf-file (70 KB) >> ]

September 2, 2008 – Cambridge, MA, USA and Vienna, Austria:

Fibrex Medical Reports Positive Phase II Results for FX06
Fibrin-derived peptide for the treatment of reperfusion injury in Myocardial Infarctio

Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.

The Phase II clinical trial of FX06 (F.I.R.E. study) in 234 patients with acute myocardial infarcts was completed in March 2008, with data indicating a statistically significant reduction in myocardial necrosis compared to placebo following intravenous application of FX06 during reperfusion treatment. FX06 is a peptide that binds to vascular endothelial (VE) cadherin, thereby inhibiting tissue inflammation and injury as well as preserving endothelial barrier function. These effects are deemed to be important for the prevention of the paradoxical additional damage to the heart muscle known as reperfusion injury.

"We are delighted that FX06 has demonstrated efficacy in this Phase II trial" stated Dr. Rainer Henning, President and CEO of Fibrex Medical. "FX06 is a first in class product and we have demonstrated that it can provide clinical benefit by preventing reperfusion injury for the huge number of patients who survive heart attacks each year. FX06 can clearly be expected to become an important addition to the armamentarium of the cardiologist in the catheter lab."

"Re-establishment of blood flow either by catheter-based balloon-intervention (PCI) or by thrombolysis, is necessary and life-saving in the treatment of acute myocardial infarctions, however such interventions can lead to tissue damage due to resulting free radicals and an acute inflammatory response," said Dan Atar, Professor of Cardiology at the Aker University Hospital, University of Oslo, Norway, who is the Coordinating Investigator for the F.I.R.E. Study. "Based on the F.I.R.E. results, we believe that FX06 can inhibit this inflammatory response and thus prevent reperfusion injury in patients. We predict that FX06 may become a novel treatment for STEMI patients undergoing PCI representing a major advance in acute cardiac care."

Fibrex is now planning an ambitious development program to bring this promising new product to registration and expect to carry this program out together with a licensing partner. This program will be discussed with regulatory agencies in US and Europe later this year.

About Fibrex Medical Inc.:
Fibrex Medical Inc. is a privately held company headquartered in Cambridge, MA, USA with operations in Vienna, Austria. The Company is developing innovative therapeutics for acute and intensive care in cardiovascular and inflammatory conditions based on novel mechanisms of action. Fibrex Medical started operations in 2001, and has raised a ¤13 M in investments from top tier venture capital investors including Atlas Venture, Global Life Science Ventures, EMBL Ventures and Mulligan Biocapital.

Acute Myocardial Infarction (AMI) and reperfusion injury:
Acute Myocardial Infarction (AMI) remains to be the number one cause of death in the developed world with approximately 2.1 million new cases per year in the USA, Western Europe and Japan. Percutaneous coronary intervention to re-establish blood flow has become the standard of care for AMI patients. While rapid reperfusion is essential to preserve myocardium, the sudden exposure of the ischemic area to blood leads to an acute inflammatory reaction causing additional damage. It is now well accepted that this process termed reperfusion injury limits clinical success of the intervention.

About the Phase II (F.I.R.E.) study:
The Phase II clinical trial of FX06 (F.I.R.E. study) randomized 234 patients with acute myocardial infarcts, to FX06 or placebo, with data indicating a statistically significant reduction in myocardial necrosis following intravenous application of 400 mg FX06 at the time of reperfusion. Detailed results are presented at the ESC Congress on 2nd September in Munich, Germany.

Magnetic resonance imaging data showed that at 5 days after the treatment, the necrotic zone of the infarct was significantly reduced by 58% with FX06 and the total zone of the left ventricle affected by the ischemia was reduced by 21% (not statistically significant). This was accompanied by a reduction of markers of muscle damage (troponin I and CK-MB). After 4 months the resulting scar was also reduced to some extent, suggesting that a reduction of reperfusion injury leads to decrease in scar formation. There were signs of clinical efficacy as well, since cardiac related serious events were also lower in FX06 treated patients (21 vs. 29 events).

November 30, 2007 – Boston MA, USA and Vienna, Austria:

Fibrex Medical Completes Enrolment of Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction
234 patients randomized for Phase II study of FX06 within 14 months

Fibrex Medical Inc., a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced that its subsidiary Fibrex Medical Research & Development GmbH has completed patient enrolment for a Phase II clinical trial of FX06 to target reperfusion injury – the damage to heart muscle that results from remedial treatment following a heart attack. FX06 acts by preventing the inflammatory response that can occur when blood flow is restored. It is this inflammatory response that results in much of the damage to heart muscle following Acute Myocardial Infarction (AMI). 234 patients for the study were randomized within 14 months.

The trial, which is referred to as the F.I.R.E (FX06 in Ischemia and REperfusion injury) study, is a double-blind placebo-controlled study involving 33 leading centres of interventional cardiology in eleven European countries. The primary endpoint is myocardial infarct size measured at five to seven days post percutaneous coronary intervention. FX06 has been administered to patients that have just suffered from AMI and the effect on heart muscle preservation during reperfusion has then been assessed using the most advanced imaging technologies, magnetic resonance imaging (CMR) and Tc99m single photon emission tomography (SPECT). FX06, through its potent inhibition of leukocyte transmigration and prevention of vascular leak, is expected to prevent reperfusion injury and reduce infarct size. The F.I.R.E. study aims to clinically demonstrate this activity.

“Completion of this study in such a short period of time is a major achievement,” stated Rainer Henning, President and CEO of Fibrex Medical. “FX06 is a first in class product, generating a lot of excitement in the interventional cardiology community. We thank all of our investigators for their dedication and commitment to this trial and our CRO, IFE Europe GmbH for a great job in organizing the trial. We are now looking forward to obtaining the results of the study which are expected after a four month follow up period in the second quarter of next year.”

“Over the last 20 years, many drugs have been tested for the prevention of reperfusion injury without much clinical success”, said Dan Atar, Professor of Cardiology at Aker University Hospital, University of Oslo, Norway, who is the Coordinating Investigator for the F.I.R.E. Study. “We are very hopeful that FX06 with its unique mechanism of action will advance to become the first effective drug for this indication.”

About Fibrex Medical Inc.
Fibrex Medical Inc. is a privately held company registered in Boston, MA, USA with operations in Vienna, Austria. The Company is developing innovative therapeutics for acute and intensive care in cardiovascular and inflammatory conditions based on novel mechanisms of action. Fibrex Medical started operations in 2001, and has raised a total of ¤13 million in capital from top tier venture capital investors including Atlas Venture, Global Life Science Ventures, EMBL Ventures and Mulligan Biocapital.

Dr. Rainer Henning
CEO
Fibrex Medical, Inc.
t:+43-(0)1-890 0617
e: info@fibrexmedical.com

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
Northbank Communications
t : +49 (0)89 57 00 18 06
e: d.pretsell[at]northbankcommunications.com

Notes to editors:
Acute Myocardial Infarction (AMI) and reperfusion injury
Acute Myocardial Infarction (AMI) remains to be the number one cause of death in the developed world with approximately 2.1 million new cases per year in the USA, Western Europe and Japan. Percutaneous coronary intervention to re-establish blood flow has become the standard of care for AMI patients. While rapid reperfusion is essential to preserve myocardium, the sudden exposure of the ischemic area to blood leads to an acute inflammatory reaction causing additional damage. It is now well accepted that this process termed reperfusion injury limits clinical success of the intervention.

How FX06 works
The process that leads to the sudden inflammatory response is caused by a massive influx of leucocyte subtypes responding to the reperfusion. FX06 is a peptide that potently inhibits the binding of fibrin E1 fragment to vascular endothelial (VE) cadherin. The drug has been shown to inhibit extravasation of major leukocyte subtypes by blocking transmigration through the endothelial layer, a bottleneck in the inflammatory cascade. In addition the drug potently prevents vascular leakage and edema formation at the site of injury.

October 9, 2006 – Wilmington DE, USA and Vienna, Austria:

Fibrex Medical Initiates Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction
First patient in for Phase II study of FX06 in Patients with Myocardial Infarction (the F.I.R.E. study)

Fibrex Medical Inc., a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced that its subsidiary Fibrex Medical Research & Development GmbH has initiated a Phase II clinical trial of FX06 to target reperfusion injury – the damage to heart muscle that results from remedial treatment following a heart attack. FX06 acts by preventing the inflammatory response, when blood flow is restored. It is this inflammatory response that results in much of the damage to heart muscle following Acute Myocardial Infarction (AMI).

The trial, which is to be called the F.I.R.E (FX06 In REperfusion) study, will be a double-blind placebo-controlled study involving 140 patients at 20 leading centres of interventional cardiology in nine European countries. The primary endpoint is myocardial salvage (tissue saved from necrosis) at five days post percutaneous coronary intervention. FX06 will be administered to patients that have just suffered from AMI and the effect on heart muscle preservation during reperfusion will then be assessed using the most advanced imaging technologies from nuclear medicine (Tc99m single photon emission tomography (SPECT) and magnetic resonance imaging (CMR). FX06 through its potent inhibition of leukocyte transmigration is expected to prevent reperfusion injury and reduce infarct size. The F.I.R.E. study aims to clinically demonstrate this activity.

“We are excited to achieve this important milestone for Fibrex Medical” stated Rainer Henning, President and CEO of Fibrex Medical. “FX06 is a first in class product with the potential to provide clinical benefit to the huge number of patients who survive their heart attack, but experience deteriorating health later in life, because the damage to their heart muscle was greater than it should have been.”

“Prevention of reperfusion injury is the last frontier in interventional cardiology”, said Dan Atar, Professor of Cardiology at the Aker University Hospital in Oslo, Norway, who is the Coordinating Investigator for the F.I.R.E. study. “We expect that FX06 will become an important addition to the armamentarium of the cardiologist in the catheter lab.”

The novel mechanism of action that Fibrex Medical has discovered to target acute inflammation also lends itself to application in other diseases involving an acute inflammatory response. Fibrex Medical is therefore exploring opportunities in hemorrhagic and septic shock, diseases with high mortality, where patients have very few treatment options.

April 6, 2006 – Vienna, Austria:

FIBREX Medical: Peptide for Myocardial Infarction Proves to be Safe

FIBREX Medical has successfully completed a first dose in man study with its lead product, the anti-inflammatory peptide FX06. FX06 is developed to prevent reperfusion injury, an undesired inflammatory reaction after acute myocardial infarction. The now completed clinical trial measured tolerability and pharmacokinetics of FX06 in healthy volunteers. The study confirmed the excellent safety profile of FX06 that has already been seen in experimental animal studies.

The entire clinical trial was performed at the Medical University of Vienna, Austria. In total, 30 healthy participants received either different doses of FX06 or a placebo. The trial's results confirmed that even in high doses FX06 was very well tolerated and no adverse effects were observed.

On the successful completion of this study Rainer Henning, CEO of FIBREX Medical, comments: "These very satisfying results allow us to progress rapidly further with our development program for FX06. Already last year, in March 2005, we were able to demonstrate FX06's efficacy in preventing reperfusion in multiple animal models in several species with a highly acclaimed paper in Nature Medicine. Now, just a year later we have finished the phase I trial and are ready to move on to the clinical trial phase II. The preparation for this proof of concept study in patients with acute myocardial infarction is well advanced. In fact, we will enrol the first patient before end of May." This phase II clinical trial, labeled the FIRE study, will prove FX06's suitability to treat myocardial infarction in 140 patients in 20 centers in seven European countries. First results will become available in May 2007.

The rapid progress of FIBREX's drug development program also has been made possible by the successful closing of a series A financing round in March 2005. Leading venture capitalists co-led by Atlas Venture and Global Life Science Ventures invested 10 million US-Dollar to this aim.

Editor's Notes:
Myocardial infarction is caused by occlusion of one or more coronary vessels. Standard treatment aims to restore blood flow as quickly as possible in order to minimize the damage to the heart. Although reperfusion is the prerequisite for tissue salvage, it induces an acute inflammatory response and in fact causes damage to the heart muscle. FX06 prevents this harmful inflammatory reaction called reperfusion injury (recent publication: Nat. Med. Vol.11:298-304; 2005).

In the USA, Europe and Japan each year more than 7,500,000 cardiac revascularization procedures are performed. The clinical success is limited by complications. Reperfusion injury ranks prominent among those complications. An effective drug for mitigation of reperfusion injury is viewed by many as the next breakthrough in cardiovascular medicine.

November 7, 2005 – Vienna, Austria:

FIBREX Medical in Clinical Development
Begins Phase I Enrolment for Lead Product FX06

FIBREX Medical Inc. announces that its subsidiary Fibrex Medical Research & Development GmbH is ready to start a first dose in man study with its lead product FX06. The study is designed to measure tolerability and pharmacokinetics in healthy volunteers. The first volunteer will be enrolled into the study in early November. Results will be available end of the year. FX06 is developed for prevention of reperfusion injury in patients with acute myocardial infarction.

"Bringing FX06 forward to testing in man in record time constitutes a major step in the development of Fibrex Medical. This phase I study will give us the confidence to move to a proof of concept-study in patient in the second quarter of 2006”, comments Rainer Henning, CEO of the company.

Myocardial infarction is caused by occlusion of one or more coronary vessels. Standard treatments aims to restore the blood flow as quickly as possible to minimize the damage to the heart. Although reperfusion is the prerequisite for tissue salvage, there is a price to pay in terms of initiation of so called reperfusion injury. Re-establishment of blood flow induces an acute inflammatory response. If unchecked, this inflammation leads to additional irreversible damage of the heart muscle, limiting the benefit of the reperfusion treatment.

In the USA, Europe and Japan each year more than 7,500,000 cardiac revascularisation procedures are performed. The clinical success is limited by complications. Reperfusion injury ranks prominent among those complications. An effective drug for mitigation of reperfusion injury is viewed by many as the next breakthrough in cardiovascular medicine.

The efficacy of FX06 in preventing reperfusion injury has been demonstrated in multiple animal models in several species. The fundamental data have been published in March in a highly acclaimed paper in Nature Medicine (Nat. Med. Vol.11:298-304; 2005). Further publications are currently under preparation.

To drive its drug development program, FIBREX closed a series A financing over 10 million US-Dollar with leading venture capitalists in March 2005. The round was co-led by Atlas Venture and Global Life Science Ventures.

August 17, 2005 – Vienna, Austria:

FIBREX Medical Receives Research Grant
FFG supports new treatment concept for sepsis

FIBREX Medical Research & Development GmbH announces the reception of public funding for the development of a new sepsis therapy. The Austrian Forschungs-Förderungs-Gesellschaft (FFG) is giving financial support until completion of phase I clinical trials. The initial funding amounts to Euro 385.000. If certain milestones are met, the total grant amount over the three year project period may reach up to Euro 1.28 million.

FIBREX develops new drugs to prevent inflammation-based tissue injury. FIBREX Medical´s most advanced product is a short peptide with the code FX06. Currently FX06 is in development for the prevention of reperfusion injury following revascularisation treatment after a myocardial infarction. Phase I clinical trials for this indication will be initiated in December 2005.
Predictive animal models have also shown significant benefit of FX06 for the treatment of sepsis. "Inflammation is necessary to defend the body against infections, but sometimes this inflammatory process gets out of control and induces destruction of healthy tissue” explains Peter Petzelbauer, the company`s CSO. A generalized uncontrolled inflammation is the major cause of sepsis; up to 50% of the patients succumb to the disease. In experimentally induced sepsis, FX06 was shown to increase survival rate to 85%.

To drive its drug development program, FIBREX closed a series A financing over 10 million US-Dollar with leading venture capitalists in March 2005. "The FFG-Grant allows us to push our sepsis project forward. We will be able to expand our team for the project. The start of the first clinical tests are planned for the end of 2008”, explains Rainer Henning, FIBREX’s CEO.

Sepsis is the leading cause of death in non-coronary intensive care units. Worldwide, approximately 1400 people a day die from sepsis. Sepsis provides a market opportunity of $2-3 billion annually for a product that truly reduces mortality. In the U.S. alone, 760.000 new cases of sepsis are recorded each year. The treatment of sepsis patients causes health care costs in excess of $20 billion worldwide.

March 14, 2005 – Wilmington, Delaware, U.S.A.:

FIBREX Medical Inc. raised US$ 10 Million Series A Financing

Wilmington, Delaware, U.S.A. – 14 March 2005
FIBREX Medical Inc. announced today that it has secured a US$ 10 million investment co-led by venture capital firms Global Life Science Ventures (GLSV) and Atlas Venture. Also joining the syndicate are EMBL Ventures, the venture vehicle of the European Molecular Biology Laboratory (EMBL), and Mulligan BioCapital AG. FIBREX is a bio-pharmaceutical company focusing on innovative therapeutics for the treatment of inflammation-based tissue injury. This series A financing will be used to progress FIBREX’s lead candidate FX06 through proof-of-concept studies in man for cardiac reperfusion injury. Dr. Rainer Henning will become Chief Executive Officer of FIBREX. Joël Besse, Senior Partner of Atlas Venture, and Dr. Holger Reithinger, Principal of GLSV, will join the company’s Board of Directors.

"The novelty of the concept, supported by excellent pre-clinical data intrigued us from the beginning. At GLSV, we constantly attempt to bring together innovative biological science, concrete medical applications and management talent. We believe we have achieved that objective by involving Dr. Rainer Henning with the work of Prof. Petzelbauer”, said Holger Reithinger.

"FIBREX is based on the exploitation of a compelling mechanism of action, which has led to the discovery of the company´s lead product FX06, a small peptide which will enter clinical development this year for the prevention of reperfusion injury after myocardial infarction. If successful, FX06 will be a first in class treatment for what represents a significant unmet medical need", said Joël Besse of Atlas Venture.

Rainer Henning, FIBREX’s new CEO comments: "We are very happy to have attracted such a distinguished group of investors to FIBREX and I am looking forward to working with them. Their participation is a strong endorsement for our innovative programs in the fields of cardiology and inflammation, in which we intend with their support to develop our pipeline going forward.”

About FIBREX Medical
FIBREX Medical Inc. and FIBREX GmbH (its subsidiary, Vienna, Austria) were founded by Prof. Dr. Petzelbauer, Head of the Endothelial Cell Biology Laboratory at the University of Vienna, and an internationally acclaimed investigator in immunology. The scientific discovery that laid the foundation for FIBREX was recently published in a contribution to Nature Medicine.

About Atlas Venture
Atlas Venture is the leading international early-stage venture capital firm, investing in life sciences, communications and information technology companies. With investing offices in Boston, London, Munich and Paris, Atlas Venture divides its investments between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages $2.1 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists who have been deeply involved in the formation and development of more than 300 companies worldwide. Since 2000, our portfolio has completed 22 IPOs and 31 acquisitions. For more information about Atlas Venture, go to www.atlasventure.com.

About Global Life Science Ventures
GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than ¤ 200 million. Up to now, GLSV has financed 27 leading biotechnology companies, nine of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology. For more information about GLSV, go to www.glsv-vc.com.

About EMBL Ventures
EMBL Ventures is an early stage venture capital investor currently managing ¤ 26 million on behalf of major institutional investors in Europe. The close relationship and proximity of EMBL Ventures to the European Molecular Biology Laboratory (EMBL) and its co-operation partners guarantees a positive impulse for the establishment of new biotech companies. EMBL Ventures invests in core technologies with global potential and is focused on life-science investments, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics.

About Mulligan BioCapital AG
Mulligan BioCapital AG is a venture capital firm dedicated to medical and healthcare technologies focusing on drug discovery and drug development companies. Investments are made in all stages of development ranging from seed stage to pre-IPO financings, as well as PIPE investments. Mulligan BioCapital invests globally, with portfolio companies currently in Europe and the US. Mulligan BioCapital’s activities go beyond financing, providing scientific and strategic support for its portfolio companies. The management team and the Supervisory Board of Mulligan BioCapital combine extensive experience in corporate finance, venture capital and healthcare, providing with it a global network in all relevant areas. For more information about Mulligan BioCapital, go to www.mulliganbio.com.

FIBREX Medical Inc. / FIBREX GmbH
Brunner Strasse 59
Vienna, 1235
Austria
Contact: Dr. Rainer Henning, CEO, rainer.henning@fibrexmedical.com

NEWS: Press Releases